ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Exelixis, Inc." (EXEL) Report Updated: Apr 21, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Exelixis, Inc." (EXEL)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: INSY, BCRX, CTIC, CRMD

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: F down no change
Last Week: F same downgrade
Two Weeks Ago: D up upgrade
service keys

"Exelixis, Inc."© quotemedia

Company Profile

Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer. Its focuses on developing cabozantinib product candidate that inhibits MET, VEGFR2, and RET proteins, which are key drivers of tumor growth, vascularization, and/or metastasis. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma, and thyroid cancer. In addition, Exelixis, Inc. is involved in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies comprising Bristol-Myers Squibb Company; Sanofi; Genentech, Inc.; GlaxoSmithKline; Merck; and Daiichi Sankyo Company Limited. Its products under development through collaborations primarily include XL475 compound; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147 and XL765 PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Recent News: "Exelixis, Inc."